Dylan Hushka appointed Chief Executive Officer
SK Capital Partners, a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s Medical division. The business has relocated its headquarters to Big Lake, Minnesota and has been renamed Precera Medical, marking its emergence as a leading contract development and manufacturing organization partner for blue chip medical device original equipment manufacturers and innovators. As part of the Transaction, LISI Group retained a minority stake in the Company.
Health Technology Insights: SimiTree Launches CLARITY for Real-Time Revenue Insights
Precera Medical is a leading CDMO focused on the production of high-precision components and assemblies serving global medical device OEMs. The Company transforms complex designs into reliable, manufacturable solutions for the most demanding applications including surgical robotics, minimally invasive surgery, orthopedics, and interventional therapies. Precera Medical operates four manufacturing sites, two in Minnesota, U.S. and two in France, with expertise in development, rapid prototyping, precision machining, precision forging and highly automated production.
In conjunction with the acquisition, Precera Medical has expanded its executive leadership team with the appointment of CDMO industry veteran Dylan Hushka as CEO. Dylan was most recently President of DuPont’s healthcare CDMO business and has held C-level, executive, commercial, and engineering roles at Spectrum Plastics Group, Nordson Medical, Vention Medical, IMDS, and Covidien (Medtronic). In addition, the Company appointed Barry Lederman as CFO. Barry was most recently CFO at Worldwide Clinical Trials and has previously partnered with SK Capital as CFO of its prior portfolio companies Perimeter Solutions and Halo Pharmaceuticals.
Health Technology Insights: Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M
Dylan Hushka, CEO of Precera Medical, said, “I am proud to join the Precera Medical team and, as a former customer, have been impressed by Precera’s world-class engineering, manufacturing, automation, quality assurance, and customer focus. With more than 75 years of contract development and manufacturing excellence, Precera continues to innovate and invest in enabling market-leading medical device OEMs to launch breakthrough technologies that impact millions of patients each year. This is a new era of precision manufacturing defined by speed, reliability, and uncompromising quality. I am excited to lead the team as we establish Precera Medical as a thriving, independent company and continue to be a true strategic extension of our customers’ teams to drive improved patient outcomes.”
In connection with the closing, Precera Medical has formed an Advisory Board (the “Board”) including several experienced industry leaders: Chris Qualters, current SK Capital Operating Director, former CEO of TekniPlex Healthcare and former EVP of Life Sciences for NN, Inc.; Art Burghouwt, former EVP of Sales, Marketing & Business Development at Tecomet; and Brian Hutchison, former CEO of Raumedic U.S. and former CEO of RTI Surgical. The Board also includes Aaron Davenport, Managing Director at SK Capital; Josh Lieberman, Principal at SK Capital; and Emmanuel Viellard, CEO of LISI Group.
Josh Lieberman said, “We are thrilled to be partnering with Dylan, the management team, LISI and the Board to support the Company’s next chapter as Precera Medical. We plan to support continued investment in capacity and expanded capabilities, both organically and through M&A, to support leading OEMs across the most advanced areas of medical technology and accelerate growth.”
Health Technology Insights: FDA Approves Interchangeable Status for Fresenius Kabi Biosimilars
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
